EUVIMEDEUVIMED entdecken
Crossref

Efficacy and Safety of Subcutaneous Pertuzumab–Trastuzumab (Phesgo) in Neoadjuvant Treatment of HER2-positive Breast Cancer: Real-world Data from Japan

Haruhito Kinoshita, Shinichiro Kashiwagi, Mariko Nishikawa, Chika Watanabe, Koji Takada, Yukie Tauchi, Kana Ogisawa, Masatsune Shibutani, Tamami Morisaki

Anticancer Research · 2026-01 · 46 (1) · 293-300

DOI: 10.21873/anticanres.17943 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Anticancer Research, online erschienen am 30.12.2025. Verfasst von Haruhito Kinoshita und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Breast Surgical Oncology, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan. Hauptthemen laut MEDLINE: Breast Neoplasms, Trastuzumab, Erb-b2 Receptor Tyrosine Kinases, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 2-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsTrastuzumabErb-b2 Receptor Tyrosine KinasesAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsHumansFemaleMiddle AgedRetrospective StudiesAgedNeoadjuvant TherapyJapanAdultTreatment OutcomeInjections, Subcutaneous

Stichwörter der Autor:innen

HER2-positive breast cancerPhesgoneoadjuvant chemotherapypertuzumabreal-world datasubcutaneoustrastuzumab

Substanzen

TrastuzumabErb-b2 Receptor Tyrosine KinasesAntibodies, Monoclonal, HumanizedpertuzumabERBB2 protein, human

Autor:innen und Institutionen

  • Department of Breast Surgical Oncology, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan.
  • Department of Breast Surgical Oncology, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan; spqv9ke9@view.ocn.ne.jp.
  • Department of Gastroenterological Surgery, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan.

Zitieren

APA

Kinoshita, H., Kashiwagi, S., Nishikawa, M., Watanabe, C., Takada, K., Tauchi, Y., Ogisawa, K., Shibutani, M., & Morisaki, T. (2026). Efficacy and Safety of Subcutaneous Pertuzumab–Trastuzumab (Phesgo) in Neoadjuvant Treatment of HER2-positive Breast Cancer: Real-world Data from Japan. Anticancer Research, 46(1), 293-300. https://doi.org/10.21873/anticanres.17943

Vancouver

Kinoshita H, Kashiwagi S, Nishikawa M, Watanabe C, Takada K, Tauchi Y, et al. Efficacy and Safety of Subcutaneous Pertuzumab–Trastuzumab (Phesgo) in Neoadjuvant Treatment of HER2-positive Breast Cancer: Real-world Data from Japan. Anticancer Research. 2026;46(1):293-300. doi:10.21873/anticanres.17943

BibTeX
@article{Kinoshita2026,
  author = {Kinoshita, Haruhito and Kashiwagi, Shinichiro and Nishikawa, Mariko and Watanabe, Chika and Takada, Koji and Tauchi, Yukie and Ogisawa, Kana and Shibutani, Masatsune and Morisaki, Tamami},
  title = {Efficacy and Safety of Subcutaneous Pertuzumab–Trastuzumab (Phesgo) in Neoadjuvant Treatment of HER2-positive Breast Cancer: Real-world Data from Japan},
  journal = {Anticancer Research},
  year = {2026},
  volume = {46},
  number = {1},
  pages = {293--300},
  doi = {10.21873/anticanres.17943}
}
Kostenlos starten →